EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Table 2 Treatment combinations among patients with a subsequent line of therapy

Subsequent line of therapy	Patients who received 1 L EGFR-TKI and had subsequent therapy (N = 160), n (%)	Patients who received 2 L+ EGFR-TKI and had subsequent therapy (N = 134), n (%)
Chemotherapy alone	25 (15.6)	29 (21.6)
Immunotherapy alone	22 (13.8)	55 (41.0)
Targeted therapies
EGFR-TKI
Alone	93 (58.1)	23 (17.2)
Plus chemotherapy	3 (1.9)	3 (2.2)
Plus immunotherapy	3 (1.9)	2 (1.5)
Plus other targeted therapies	2 (1.3)	2 (1.5)
Plus chemotherapy, other targeted therapies	1 (0.6)	3 (2.2)
Other targeted therapies
Alone	4 (2.5)	2 (1.5)
Plus chemotherapy	6 (3.8)	14 (10.4)
Clinical study drug^a	1 (0.6)	1 (0.7)

1 L first line, 2 L+ second or later line, EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor
^a Flatiron Health masks the names of clinical study drugs in the data due to the sensitive nature of patients in clinical trials

ISSN: 1471-2407